Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab and Docetaxel in Metastatic Non-Small Cell Lung Cancer
NCT06532032Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of amivantamab in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Jul 2024; status: completed.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06532032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532032.